EUVIMEDEUVIMED entdecken
Crossref

The Case for Pediatric Participation in Risky First‐In‐Human Clinical Trials

Christopher Bobier iD, Anthony Merlocco, Daniel J Hurst iD

Bioethics · 01.11.2026

DOI: 10.1111/bioe.70206 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioethics, online erschienen am 01.11.2026. Verfasst von Christopher Bobier und 2 weiteren Autor:innen. Beteiligte Einrichtung: Central Michigan University College of Medicine, Mt Pleasant, Michigan, USA. Die Arbeit nennt 51 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The purpose of a first‐in‐human (FIH) clinical trial is to gather safety, side effects, and (potential) dosage information, which is to say, information about how an intervention affects and interacts with the human body. Although participants in FIH trials may personally benefit, the primary goal is to obtain participant baseline human safety knowledge or knowledge of intervention efficacy. Some FIH clinical trials carry significant foreseeable risk to participants with little to no foreseeable participant benefit. As the potential risk is high and personal benefit unlikely, there is consensus that participants in risky FIH trials should consent to participate, which entails that children should not be included in a risky FIH trial that could enroll only adults. We take aim at this view and argue that risky FIH trials planned for adults should be open also to including children in some circumstances. Specifically, and focusing primarily on solid organ xenotransplant research, we argue that considerations of generalizability, fair inclusion, differential risk‐benefit, parental authority, and children's interest are ethically salient, and that concerns of exploitation, instrumentalization, and upper‐limits of harm can be effectively addressed.

Schlagwörter

Stichwörter der Autor:innen

exploitationpediatric xenotransplantationphase I clinical trialrisk‐benefitvulnerable population

Autor:innen und Institutionen

  • Central Michigan University College of Medicine, Mt Pleasant, Michigan, USA.
  • University of Tennessee Health Science Center and LeBonheur Children's Hospital, Memphis, Tennessee, USA.
  • Rowan-Virtua School of Osteopathic Medicine, Stratford, New Jersey, USA.

ORCID-Profile: Christopher Bobier, Daniel J Hurst

Zitieren

APA

Bobier, C., Merlocco, A., & Hurst, D. J. (2026). The Case for Pediatric Participation in Risky First‐In‐Human Clinical Trials. Bioethics. https://doi.org/10.1111/bioe.70206

Vancouver

Bobier C, Merlocco A, Hurst DJ. The Case for Pediatric Participation in Risky First‐In‐Human Clinical Trials. Bioethics. 2026. doi:10.1111/bioe.70206

BibTeX
@article{Bobier2026,
  author = {Bobier, Christopher and Merlocco, Anthony and Hurst, Daniel J},
  title = {The Case for Pediatric Participation in Risky First‐In‐Human Clinical Trials},
  journal = {Bioethics},
  year = {2026},
  doi = {10.1111/bioe.70206}
}
Kostenlos starten →